Sarepta Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	613.08	1,103	428.43	966.78	2,116	1,503
Short-Term Investments	237.92	251.78	1,248	1,023	-	435.92
Cash & Short-Term Investments	850.99	1,355	1,676	1,989	2,116	1,939
Cash Growth	-28.99%	-19.18%	-15.74%	-5.98%	9.15%	72.36%
Accounts Receivable	524.45	636.6	430.11	256.39	171.64	135.52
Other Receivables	17.16	13.13	6.86	5.21	0.01	3.06
Receivables	541.6	649.73	436.98	261.6	171.65	138.58
Inventory	1,077	749.96	322.86	203.97	186.21	231.96
Prepaid Expenses	29.85	30.67	27.64	29.64	30.31	32.65
Other Current Assets	222.7	288.32	115.61	73.28	100.06	143.43
Total Current Assets	2,722	3,073	2,579	2,558	2,604	2,485
Property, Plant & Equipment	498.1	488.65	357.11	244.99	236.69	282.19
Long-Term Investments	9.21	136.87	6.53	31.32	34.89	38.8
Other Intangible Assets	29.68	26.89	29.62	7.58	14.24	13.63
Other Long-Term Assets	231.86	237.3	291.99	286.62	258.06	164.9
Total Assets	3,493	3,963	3,265	3,128	3,148	2,985
Accounts Payable	94.02	214.44	164.92	95.88	76.74	111.09
Accrued Expenses	157.68	241.66	197.93	335.67	206.45	147.42
Current Portion of Long-Term Debt	-	-	105.48	-	-	-
Current Portion of Leases	10.17	13.27	-	15.49	-	-
Current Income Taxes Payable	9.09	17.39	13.77	12.52	0.22	-
Current Unearned Revenue	485.45	130.26	50.42	89.24	89.24	89.24
Other Current Liabilities	165.02	114.66	121.15	70.8	80.08	68.27
Total Current Liabilities	921.43	731.68	653.66	619.6	452.73	416.03
Long-Term Debt	1,035	1,137	1,133	1,544	1,097	992.49
Long-Term Leases	215.04	192.47	140.97	57.58	41.51	80.37
Long-Term Unearned Revenue	-	325	437	485	574.24	663.49
Other Long-Term Liabilities	1.7	49.15	41.1	36.94	54.6	70.59
Total Liabilities	2,173	2,435	2,405	2,743	2,220	2,223
Common Stock	0.01	0.01	0.01	0.01	0.01	0.01
Additional Paid-In Capital	5,987	5,739	5,305	4,297	4,135	3,610
Retained Earnings	-4,642	-4,211	-4,446	-3,910	-3,207	-2,848
Comprehensive Income & Other	0.22	-0.22	0.92	-1.66	-0.02	0
Shareholders' Equity	1,320	1,528	859.34	384.95	928.01	761.76
Total Liabilities & Equity	3,493	3,963	3,265	3,128	3,148	2,985
Total Debt	1,260	1,343	1,379	1,617	1,138	1,073
Net Cash (Debt)	-409.36	11.92	297.29	372.02	977.48	865.71
Net Cash Growth	-	-95.99%	-20.09%	-61.94%	12.91%	119.10%
Net Cash Per Share	-4.18	0.11	3.22	4.25	12.03	11.11
Filing Date Shares Outstanding	104.79	97.03	93.86	87.98	87.15	79.42
Total Common Shares Outstanding	104.77	96.9	93.73	87.95	87.13	79.37
Working Capital	1,801	2,342	1,926	1,938	2,151	2,069
Book Value Per Share	12.60	15.77	9.17	4.38	10.65	9.60
Tangible Book Value	1,290	1,501	829.72	377.37	913.77	748.13
Tangible Book Value Per Share	12.32	15.49	8.85	4.29	10.49	9.43
Land	-	10.17	10.17	5.18	5.18	5.18
Buildings	-	51.18	48.06	47.94	47.61	39.4
Machinery	-	141.98	118.63	102.31	75.04	57.76
Construction In Progress	-	165.9	91.09	23.59	25.16	71.54
Leasehold Improvements	-	155.07	99.99	97.33	103.37	55.02

Source: S&P Global Market Intelligence. Standard template. Financial Sources.